Introduction

Hypericin is a natural polycyclic aromatic dianthraquinone present in the St. John’s Wort plant (Hypericum perforatum). It has been used as a traditional herbal medicine since ancient times for its anti-viral, anti-bacterial, and anti-inflammatory properties as well as to treat depression. In recent years, it has attracted increasing interest due to its potential as an effective photosensitizer used in photodynamic therapy (PDT) to fight various cancers.

The isolation of pure hypericin from Hypericum perforatum is a tedious procedure due to its very low content in the plant (0.03 to 0.09%) and poor solubility in solvents. To meet the needs of hypericin demand both from academic and industrial areas, great efforts have been made in the past to develop a way for it to be chemically synthesized. The first step towards the successful chemical synthesis of hypericin dates back to 1957, when Brockmann and his co-workers for the first time reported a total synthetic pathway of hypericin. Their pathway started from 3,5-dimethoxybenzoic acid methyl ester and involved 12 steps in total that resulted in a low overall yield of hypericin of 6% to 9%.

In recent years, it has finally photocyclized to hypericin upon irradiation of visible light overnight in a moderate yield of 56% (overall yield was 51.6%). Although the overall yield was later increased to 74% by the same group by introducing microwave assistance in the synthesis of protohypericin, the reaction was carried out in a toxic organic solvent DMF and in the presence of a corrosively reactive organic base potassium t-butoxide. Additionally, the photocyclization step of protohypericin to hypericin took place overnight with a 500 W halogen lamp. Therefore, it is necessary to find an efficient pathway for the synthesis of hypericin, where the required reactions can be performed under mild conditions, the solvents involved in each step are less or non-toxic, easy to handle after the reactions, and would preferably be water based to comply with the standpoints of green chemistry.

In this paper, as shown in Scheme 1, a greatly more efficient, facile and environmentally friendly method for the synthesis of hypericin (7a) was developed. This method started with the easily available emodinanthraquinone, from where its precursor protohypericin was obtained in water by using microwaves and the irradiation of protohypericin in acetone with 575 nm visible light. This method resulted in a high hypericin overall yield. Furthermore, we delightedly found that the strategy could be successfully adapted for the synthesis of the derivatives of hypericin (7b–d), which are especially effective photosensitizers used in photodynamic therapy (PDT) to treat depression.
significant in new photosensitizer discovery\textsuperscript{18,19} used in cancer photodynamic therapy.

**Experimental**

**General remarks**

All reagents and solvents were purchased from commercial suppliers and used without further purification unless specified. Dimethyl sulfate, N-bromosuccinimide (NBS), 18-crown-6 and benzoyl peroxide (BPO) were purchased from Energy Chemical Reagent Co. Triphenyl phosphine and tin(II) chloride dehydrate (SnCl\textsubscript{2}·2H\textsubscript{2}O) were purchased from Sinopharm Chemical Reagent Co. Butylaldehyde was purchased from TCI. Benzaldehyde was purchased from Aladdin. Ferrous sulfate heptahydrate (FeSO\textsubscript{4}·7H\textsubscript{2}O) was purchased from Tianjin Bodi Chemical Co., Ltd. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Aladdin. Ferrous sulfate heptahydrate (FeSO\textsubscript{4}·7H\textsubscript{2}O) was purchased from Tianjin Bodi Chemical Co., Ltd. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Kehao Biotech Co., Ltd. Flash chromatography (eluent: petroleum ether/ethyl acetate = 4:1, v/v) to give 5a as a pale yellow solid (0.3 g, 92%).\textsuperscript{1}H NMR (500 MHz, DMSO·D\textsubscript{6}) \(\delta 12.37 (s, 1H), 12.29 (s, 1H), 10.99 (s, 1H), 7.46 (s, 1H), 7.27 (s, 1H), 6.45–6.43 (m, 1H), 6.25 (d, \(J = 2.7, 1H), 4.42 (s, 2H)\) ppm.\textsuperscript{24}

\[\text{1,3,8-Trihydroxy-6-methylanthracen-9(10H)-one (5a). Compound 5a was synthesized by following a published procedure.}\textsuperscript{23} To a 250 mL flask, emodin (1.36 g, 5.0 mmol) was stirred in 100 mL glacial acetic acid (98%) at 60 °C. Then SnCl\textsubscript{2}·2H\textsubscript{2}O (7.9 g, 35 mmol) dissolved in 50 mL concentrated hydrochloric acid was added dropwise into the flask. Then this resulting solution was refluxed for 2 h, which was then poured into ice water. The precipitate formed was filtered, washed with deionized water, and then vacuum dried. The crude was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate = 4:1, v/v) to give 5a as a pale yellow solid (1.23 g, 96%).\textsuperscript{2}H NMR (500 MHz, DMSO·D\textsubscript{6}) \(\delta 13.24 (br, 1H), 12.29 (s, 1H), 12.22 (s, 1H), 10.99 (s, 1H), 7.46 (s, 1H), 7.27 (s, 1H), 6.44–6.43 (m, 1H), 6.25 (d, \(J = 2.7, 1H), 4.42 (s, 2H)\) ppm.\textsuperscript{24}

\[\text{1,3,8-Trihydroxy-6-pentylanthracen-9(10H)-one (5c). Compound 5c was synthesized by following a published procedure with modification.}\textsuperscript{22} To a 25 mL flask, compound 4 (300 mg, 1.0 mmol) was dissolved in 20 mL glacial acetic acid at 60 °C. To this solution, SnCl\textsubscript{2}·2H\textsubscript{2}O (1.59 g, 7.0 mmol) dissolved in 11 mL concentrated hydrochloric acid was added drop wise. Then this resulting solution was refluxed for 2 h, which was then poured into ice water. The precipitate formed was filtered, washed with deionized water, and vacuum dried. The crude was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate = 6:1, v/v) to give 5c as a pale yellow solid (33.6 mg, 71%).\textsuperscript{1}H NMR (500 MHz, DMSO·D\textsubscript{6}) \(\delta 12.37 (s, 1H), 12.20 (s, 1H), 10.81 (s, 1H), 6.77 (s, 1H), 6.66 (s, 1H), 6.41 (d, \(J = 1.3, 1H), 6.23 (d, \(J = 2.2, 1H), 4.29 (s, 2H), 2.55 (t, \(J = 7.45, 2H), 1.60–1.54 (m, 2H), 1.34–1.23 (m, 4H), 0.86 (t, \(J = 7.0, 3H)\) ppm.\textsuperscript{1}C NMR (125 MHz, DMSO·D\textsubscript{6}) \(\delta 191.0, 165.0, 164.5, 161.7, 151.7, 145.0, 141.9, 119.1, 114.4, 113.0, 108.4, 107.3, 100.9, 35.4, 32.3, 30.9, 29.8, 21.9, 13.9 ppm. HRMS: m/z calculated for C\textsubscript{19}H\textsubscript{20}O\textsubscript{4} [M + H]\textsuperscript{+} 313.1440, found 313.1439. M.p.: 161.4–162.0 °C.

\[\text{1,3,8-Trihydroxy-6-methylanthracen-9(10H)-one (5d). Compound 5d was synthesized by following a published procedure with modification.}\textsuperscript{22} To a 100 mL flask, compound 4 (40 mg, 0.85 mmol) was dissolved in 30 mL acetic acid. To this resulting solution, SnCl\textsubscript{2}·2H\textsubscript{2}O (1.53 g, 6.8 mmol) dissolved in 20 mL 33% HBr was added drop wise. After being refluxed for 1.5 h, the reaction mixture was then poured into ice water. The precipitate formed was filtered, washed with deionized water, and vacuum dried. The crude was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate = 6:1, v/v) to give 5d as a pale yellow solid (265 mg, 90%).\textsuperscript{1}H NMR (500 MHz, DMSO·D\textsubscript{6}) \(\delta 13.27 (s, 1H), 12.20 (s, 1H), 10.81 (s, 1H), 6.77 (s, 1H), 6.66 (s, 1H), 6.41 (d, \(J = 1.3, 1H), 6.23 (d, \(J = 2.2, 1H), 4.29 (s, 2H), 2.55 (t, \(J = 7.45, 2H), 1.60–1.54 (m, 2H), 1.34–1.23 (m, 4H), 0.86 (t, \(J = 7.0, 3H)\) ppm.\textsuperscript{1}C NMR (125 MHz, DMSO·D\textsubscript{6}) \(\delta 191.0, 165.0, 164.5, 161.7, 151.7, 145.0, 141.9, 119.1, 114.4, 113.0, 108.4, 107.3, 100.9, 35.4, 32.3, 30.9, 29.8, 21.9, 13.9 ppm. HRMS: m/z calculated for C\textsubscript{19}H\textsubscript{20}O\textsubscript{4} [M + H]\textsuperscript{+} 313.1440, found 313.1439. M.p.: 161.4–162.0 °C.

**Scheme 1** General synthetic pathway of hypericin (7a) and its derivatives (7b–d). Reagents and conditions: (1) 1.5% NaOH/H\textsubscript{2}O\textsubscript{2}, pyridine-N-oxide, FeSO\textsubscript{4}·7H\textsubscript{2}O, 105 °C, 10 W, 70 min, N\textsubscript{2} by microwave reactor; (2) 575 nm monochromatic light, acetone, N\textsubscript{2}, 60 min.
MHZ, DMSO-d$_6$) δ 12.37 (s, 1H), 12.21 (s, 1H), 10.85 (s, 1H), 7.30–7.23 (m, 4H), 7.20–7.15 (m, 1H), 6.85 (s, 1H), 6.74 (s, 1H), 6.43 (d, $J = 1.2$ Hz, 1H), 6.22 [d, $J = 2.1$ Hz, 1H], 4.30 (s, 2H), 2.93–2.85 (m, 4H) ppm. $^{13}$C NMR (125 MHz, DMSO-d$_6$) δ 191.1, 165.0, 164.6, 161.7, 150.7, 145.0, 142.0, 141.2, 128.4, 128.3, 126.0, 119.3, 114.6, 113.2, 108.4, 107.1, 101.0, 37.2, 36.0, 32.4 ppm. HRMS: m/z calcd for C$_{22}$H$_{18}$O$_4$ [M + H]$^+$ 347.1283, found 347.1281. M.p.: 196.7–197.1 °C.

**General procedure for the synthesis of protohypericin and its derivatives**

To a microwave 10 mL tube, 5a, 5b, 5c, or 5d (0.5 mmol, 1 equiv.), pyridine-N-oxide (2.5 mmol, 5 equiv.), FeSO$_4$·7H$_2$O (10 mg, 36 μmol), and NaOH (40 mg, 1.0 mmol) were dissolved in 2 mL ultrapure water. The mixture was placed in a microwave reactor at 10 W, 105 °C under argon atmosphere for 70 min. The reaction mixture was then cooled to room temperature, and was acidified with 3% hydrochloric acid. The precipitate was filtered, washed with deionized water, and vacuum dried. The purification with column chromatography on silica gel by using petroleum ether/ethyl acetate/methanol (4:8:1, v/v/v) as eluent gave 6a–d, respectively.

**Protohypericin (6a).** Purple solid (122 mg, 96%). $^1$H NMR (500 MHz, DMSO-d$_6$) δ 14.36 (br, 2H), 12.86 (br, 2H), 7.20 (s, 2H), 6.74 (s, 2H), 6.33 (s, 2H), 2.05 (s, 6H) ppm.$^{25}$

$^{1,3,4,6,8,15}$-Hexahydroxy-7,16-dioxy-7,16-dihydrodibenzo[a,o]perylen-10,13-diacarbonylic acid (6b). Purple solid (270 mg, 96%). $^1$H NMR (500 MHz, DMSO-d$_6$) δ 14.69 (s, 2H), 14.47 (s, 2H), 7.77 (s, 2H), 7.73–7.69 (m, 1H), 7.68–7.63 (m, 1H), 6.62 (s, 2H) ppm.$^{25}$

$^{1,3,4,6,8,15}$-Hexahydroxy-10,13-dipentyl dibenzo[a,o]perylen-7,16-dione (6c). Purple solid (140 mg, 90%). $^1$H NMR (500 MHz, DMSO-d$_6$) δ 14.37 (s, 2H), 12.84 (s, 2H), 7.19 (s, 2H), 6.73 (s, 2H), 6.33 (s, 2H), 2.39–2.21 (m, 4H), 1.38–1.07 (m, 12H), 0.80 (t, $J = 6.9$ Hz, 6H) ppm. $^{13}$C NMR (125 MHz, DMSO-d$_6$) δ 184.4, 174.0, 168.3, 160.0, 147.5, 136.4, 129.8, 127.9, 125.3, 119.6, 115.4, 113.5, 108.9, 107.8, 101.4, 40.5, 40.3, 40.2, 40.0, 39.8, 39.7, 39.5, 35.8, 32.8, 31.4, 30.3, 22.4, 14.4 ppm. HRMS: m/z calcd for C$_{38}$H$_{32}$O$_8$ [M + H]$^+$, 617.2175, found: 617.2176.

$^{3,4}$-Dibenzyl-1,6,8,10,11,13-hexahydroxyphenanthro[1,10,9,8-opqra]perylen-7,14-dione (7d). Purple solid (160.6 mg, 94%). $^1$H NMR (500 MHz, MeOD) δ 7.34 (s, 2H), 6.75 (s, 2H), 6.35–6.21 (m, 6H), 6.12–6.00 (m, 4H), 3.80–3.69 (m, 2H), 3.34–3.45 (m, 2H), 2.76–2.67 (m, 2H), 2.13–2.03 (m, 2H) ppm.$^{13}$C NMR (125 MHz, MeOD) δ 185.89, 172.4, 167.9, 162.6, 147.1, 139.1, 127.6, 127.0, 126.7, 125.7, 124.4, 121.9, 120.9, 118.1, 117.2, 108.9, 105.6, 103.1, 39.0, 38.9 ppm. HRMS: m/z calcd for C$_{44}$H$_{34}$O$_8$ [M + H]$^+$, 685.1857, found: 685.1858. M.p. > 300 °C.

**Cell culture**

The breast cancer cell line (MCF-7), human hepatoma cell line (HepG-2) and the human skin basal cell carcinoma (A431) were obtained from American Type Culture Collection. MCF-7 and A431 cells were cultured at 37 °C under a humidified 5% CO$_2$ in DMEM (Dulbecco's Modified Eagle Medium) medium supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin; and HepG-2 cells were cultured in the same way except the culture medium used was RPMI 1640.

**Cell viability assay**

The relative cell viability of compound 7a (7b, 7c, or 7d) was evaluated in vitro by MTT assay. HepG-2, MCF-7 or A431 cells were seeded respectively in 96-well plates at a density of 5 × 10$^4$ cells per well in 100 μL RPMI 1640 or DMEM medium, and grew for 24 h at 37 °C. Then the medium was replaced by 90 μL fresh medium and 10 μL 7a (7b, 7c, or 7d) in PBS (containing 0.2% DMSO-d$_6$) at different concentrations (0.2, 0.4, 0.6, 0.8, 1.0 μM). After 4 h incubation, the cells were washed with PBS for 3 times, and then fresh medium was added. The cells were exposed to a LED array photosource ($\lambda = 595$–600 nm, 8.6 mW cm$^{-2}$) for 30 min, and further cultured for 24 h at 37 °C. Then 10 μL fresh medium containing MTT (5 mg mL$^{-1}$) was added to each well. After 4 h incubation, 100 μL DMSO was added to each well to dissolve formazan crystals. Finally, the plate was gently shaken for 10 min and the absorbance at 490 nm was recorded with a microplate reader.
Results and discussion

Reaction optimization for synthesis of protohypericin

Protohypericin was the key precursor to the synthesis of hypericin, therefore the dimerization of emodinanthrone leading to protohypericin was recognized as the key step in this method.\textsuperscript{16} The synthesis of protohypericin has been extensively studied, which can be summarized in two methods based on starting materials, (1) emodin-type:\textsuperscript{16,26} by using potassium hydroxide as a base, protohypericin can be synthesized in the presence of hydroquinone in water. The drawbacks are extremely long reaction time (7–20 days) and low yield (25–72%); (2) emodinanthrone-type:\textsuperscript{16,17} by using potassium t-butoxide or piperidine as a base, protohypericin can be obtained in a moderate yield (70–78%) in a short time. While the drawbacks here are the requirement of notorious organic solvents (DMF or pyridine) and a still unsatisfying yield. Based on the discoveries previously reported in the literature, we chose emodinanthrone as a starting material for our method in order to pursue the development of an economic, green, and efficient synthetic method of protohypericin. In our method, the dimerization of emodinanthrone was performed in a microwave reactor by using cheap and easy to handle inorganic bases (such as NaOH, KOH, and LiOH) as a replacement for the organic bases, and water as solvent instead of the organic solvents. The reaction conditions were varied to study their effect on the yield, and the results were summarized in Table 1.

The various parameters, including the amount of pyridine N-oxide (PNO), catalyst, FeSO$_4 \cdot$7H$_2$O, base, reaction temperature and time, were thoroughly investigated. As shown in Table 1, the presence of pyridine N-oxide (PNO) and a suitable redox catalyst in the reaction were crucial for the reaction, with either absence leading to failure. For example, in the absence of PNO, 6a was obtained with only 6% yield, which demonstrated that PNO was an indispensable oxygen transfer reagent in this reaction system. While the absence of FeSO$_4 \cdot$7H$_2$O led to no reaction at all.\textsuperscript{3} In addition, ferric chloride could be used to substitute FeSO$_4 \cdot$7H$_2$O without compromise of the yield\textsuperscript{4} but copper chloride could not.\textsuperscript{5} The variation of the amount of PNO did not influence the yield much provided that the other reaction conditions were kept unchanged,\textsuperscript{1,7,8} where the best yield of 96% was obtained when PNO was 5 equivalents;\textsuperscript{1,11} The

| Entry | PNO (equiv.) | Catalyst (equiv.\textsuperscript{b}) | Base | $T$ (°C) | $t$ (min) | Yield\textsuperscript{c} (%) |
|-------|-------------|-------------------------------------|------|----------|----------|-----------------------------|
| 1\textsuperscript{a} | 5.0 | 0.08 | 1.5% NaOH | 105 | 70 | 96 |
| 2 | — | 0.08 | 1.5% NaOH | 105 | 70 | 6 |
| 3 | 5.0 | — | 1.5% NaOH | 105 | 70 | N.D |
| 4 | 3.2 | 0.08\textsuperscript{d} | 6.0% NaOH | 105 | 70 | 94 |
| 5 | 5.2 | 0.08\textsuperscript{e} | 6.0% NaOH | 105 | 70 | Very low |
| 6 | — | 3.6\textsuperscript{f} | 6.0% NaOH | 105 | 70 | N.D |
| 7 | 3.5 | 0.08 | 1.5% NaOH | 105 | 70 | 93 |
| 8 | 4.5 | 0.08 | 1.5% NaOH | 105 | 70 | 91 |
| 9 | 5.0 | 0.08 | 0.5% NaOH | 105 | 70 | 77 |
| 10 | 5.0 | 0.08 | 1.0% NaOH | 105 | 70 | 94 |
| 11 | 5.0 | 0.08 | 2.0% NaOH | 105 | 70 | 96 |
| 12 | 5.0 | 0.08 | 5.0% NaOH | 105 | 70 | 76 |
| 13 | 5.0 | 0.08 | 1.5% LiOH | 105 | 70 | 71 |
| 14 | 5.0 | 0.08 | 3.6% LiOH | 105 | 70 | 95 |
| 15 | 5.0 | 0.08 | 1.5% KOH | 105 | 70 | 77 |
| 16 | 5.0 | 0.08 | 2.1% KOH | 105 | 70 | 93 |
| 17 | 5.0 | 0.08 | 1.5% NaOH | 90 | 70 | 72 |
| 18 | 5.0 | 0.08 | 1.5% NaOH | 100 | 70 | 90 |
| 19 | 5.0 | 0.08 | 1.5% NaOH | 120 | 70 | 88 |
| 20 | 5.0 | 0.08 | 1.5% NaOH | 105 | 50 | 86 |
| 21 | 5.0 | 0.08 | 1.5% NaOH | 105 | 60 | 90 |
| 22 | 5.0 | 0.08 | 1.5% NaOH | 105 | 80 | 89 |
| 23 | 5.0 | 0.08 | 1.5% NaOH | 105 | 90 | 90 |

\textsuperscript{a} The optimized conditions: 5a, 120 mg, 1 equivalent; microwave, 10 W; water (2 mL); N$_2$ atmosphere. \textsuperscript{b} The catalyst was FeSO$_4 \cdot$7H$_2$O unless specified. \textsuperscript{c} Isolated yield. N.D: no detection. \textsuperscript{d} The catalyst was FeCl$_3$. \textsuperscript{e} The catalyst was CuCl$_2$. \textsuperscript{f} O$_2$ atmosphere.
base, such as NaOH, helps to dissolve emodinanthrone in the reaction mixture and has obvious influence on the yield. A concentration of NaOH lower than 0.5% or higher than 5% decreased the yield from over 90% to about 76%. It's worth to mention that LiOH and KOH, which have similar chemical properties as NaOH, gave more or less equally good yields (95% for LiOH and 93% for KOH), although the concentration of the two hydroxides used was slightly higher than that of NaOH. The study on the effect of reaction temperature disclosed that the yield increased with the temperature and reached to a peak value (96% at 105°C) (Fig. 1a). The study on the effect of reaction temperature disclosed that the yield increased with the temperature and reached to a peak value (96% at 105°C; see Falk et al.1); further increase of the temperature did not benefit a higher yield, for instance, 88% was obtained at 120°C.7 This might be ascribed to the possibility that high temperature led to side reactions, such as the oxidation of hydroxyl groups in emodinanthrone. The screening on reaction time proved that the yield increased with the reaction time and reached the best yield of 96% at 70 min.1 After this point, the yield decreased slightly with the reaction time with about 6%,10,26 which may due to the decomposition of protohypericin in the hot basic solution.

Notably, the reaction can be carried out in gram-scale with 91.6% yield under the optimized conditions (see ESI†).

**Synthesis of hypericin and its derivatives**

It was known that a major method to obtain hypericin was the photocyclization of protohypericin irradiated with visible light. The light sources reported previously include sunlight,27 halogen,17 glow,29 and high-/low-pressure mercury lamps.1 The reaction time varied from 10 min claimed by Falk et al.1 to 24 h by Kim et al.29 as well as the yield from 31% to 92%. We speculated the enormous variation of the reaction time and yield might result from the emission difference of the light sources.

The UV-Vis spectra of 6a and 7a were shown in Fig. 1a. Considering20,27,28 protohypericin has a strong absorption band at 525–590 nm while no obvious absorption for 7a at 575 nm, we chose monochromatic lamps with a maximum emission peak at 575 nm as visible light source (Fig. 1b) to perform the photocyclization of 6a. The monitoring of the reaction by TLC displayed that the reaction was completed at 1 h, where an isolated yield of 96% was obtained by flash chromatography. The reaction has very good reproducibility and can be performed on large scale with little compromise to the yield (89.8%, see ESI†).

To study the applicability of the synthetic pathway developed above, the derivatives of hypericin with different substituents were synthesized accordingly, where methyl groups on 10- and 11- positions in hypericin (7a) were replaced with carboxyl groups for 7b, pentyl groups for 7c, and phenethyl groups for 7d, respectively. As described in Scheme 1, starting with 5b–c, the analogues of emodinanthrone 5a, respective 6b–d were successfully synthesized with satisfying to excellent isolated yields (90–96%) under the optimized conditions screened for 5a, which were subjected to irradiation of visible light to give corresponding 7b–d with excellent yields (94–96%). This indicates that the synthetic pathway developed in the present work has good applicability for the derivatives of hypericin, which is significant in photosensitizer discovery based on natural bioactive molecules.

**Photodynamic therapy study**

Photodynamic therapy (PDT) is a noninvasive technique that is used to treat and detect small and superficial tumors.29–34 Hypericin has been regarded as an effective natural photosensitizer,35–37 and has gained increasing attention as a potential alternative treatment for various cancers due to its unique photochemical properties and photobiological activities.9,38–41 To explore the potential of the three derivatives 7b–d as photosensitizer for PDT, A431, HepG-2, and MCF-7 cell lines were used for cell cytotoxicity evaluation at a concentration range of 0.2–1.0 μM with MTT assay. For comparison, hypericin was used as a control. As displayed in Fig. 2, 7b showed better
cytotoxicity to the test cell lines than 7a, while the cytotoxicity of 7c and 7d were much less than that of 7a at the same concentrations. This may be attributed to the better water solubility of 7b. The results imply that the properties of the substituents on position of 10- and 11- in hypericin molecules are strongly related to its photocytotoxicity: changing methyl groups to hydrophilic ones (such as –COOH for 7b) can enhance the hydrophilicity of a resulting compound and hence create a better photocytotoxicity; on contrary, the more hydrophobic and steric the substituents, the worse the photocytotoxicity (for instance, comparing methyl groups in 7a with pentyl in 7c or phenethyl in 7d). These founding are in line with those reported in the literature.

Conclusions

In summary, we developed an economic, green and highly efficient synthetic pathway for preparing hypericin and its derivatives under mild reaction conditions. Water was used as the solvent in the key step of emodinanthrone dimerization. The reaction time of the photocyclization of protohypericin was greatly shortened to 1 h. Furthermore, the PDT effect of 7b is better than those of 7a, 7c and 7d. These results indicate the derivatives of hypericin synthesized in the present work have the potential as photosensitizers for fighting cancers.

Conflicts of interest

The authors declare no competing financial interest.

Acknowledgements

This research work was supported by the National Natural Science Foundation of China (21772157, 21572181 and 21174113) to the Project of Science and Technology of Social Development in Shaanxi Province (2016SF-029) and Yangling Demonstration Zone (2016SF-029).

References

1 H. Falk, From the photosensitizer hypericin to the photoreceptor stentor-in-the chemistry of phananthroperylenes quinones, Angew. Chem., 1999, 38, 3117–3136.
2 J. Barnes, L. A. Anderson and J. D. Phillipson, St John’s Wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties, J. Pharm. Pharmacol., 2001, 53, 583–600.
3 K. Souvik, L. Marc, Z. Sebastian and S. Michael, An endophytic fungus from Hypericum perforatum that produces hypericin, J. Nat. Prod., 2008, 71, 159–162.
4 P. S. Martin, C. Anthony, J. C. Marie, C. D. Jean and N. Michel, Hypericin activates l-type ca2+ channels in cardiac myocytes, J. Nat. Prod., 2007, 70, 510–514.
5 K. Souvik, Z. Sebastian, K. Ján, C. Eva and S. Michael, Light-independent metabolomics of endophytic thielavia subthermophila provides insight into microbial hypericin biosynthesis, J. Nat. Prod., 2009, 72, 1825–1835.
6 N. Adolf and B. Veronika, Lessons learned from herbal medicinal products: the example of St. John’s Wort, J. Nat. Prod., 2010, 73, 1015–1021.
7 K. Michalska, H. Fernandes, M. Sikorski and M. Jaskolski, Crystal structure of Hyp-1, a St. John’s Wort protein implicated in the biosynthesis of hypericin, J. Struct. Biol., 2010, 169, 161–171.
8 A. Kamuhabwa, P. Agostinis, B. Ahmed, W. Landuyt, B. Van Cleyrenbreugel, H. Van Poppel and P. de Witte, Hypericin as a potential phototherapeutic agent in superficial transitional cell carcinoma of the bladder, Photochem. Photobiol. Sci., 2004, 3, 772–780.
9 K. Gyuraszova, J. Mikes, A. Halaburkova, R. Jendzelovsky and P. Fedorocko, YM155, a small molecule inhibitor of survivin expression, sensitizes cancer cells to hypericin-mediated photodynamic therapy, Photochem. Photobiol. Sci., 2016, 15, 812–821.
10 J. T. Wessels, A.-C. Busse, M. Rave-Fraenk, S. Zaenker, R. Hermann, E. Grabbe and G.-A. Mueller, Photosensitizing and radiosensitizing effects of hypericin on human renal carcinoma cells in vitro, Photochem. Photobiol., 2007, 84, 228–235.
11 P. Mauri and P. Pietta, High-performance liquid chromatography/electrospray mass spectrometry of Hypericum perforatum extracts, Rapid Commun. Mass Spectrom., 2000, 14, 95–99.
12 H. Brockmann, F. Kluge and H. Muxfeldt, Total synthesis of hypericin, Chem. Ber., 1957, 90, 2302–2318.
13 J. Banville and P. Brassard, Reactions of ketene acehtals. 8. Simple syntheses of the methyl ester-ethers of the anthraquinones endocrocin, pitromelic acid, and clavorubin, J. Org. Chem., 1976, 41, 3018–3020.
14 Y. Hirose, M. Kuroiwa, H. Yamashita, T. Tanaka and T. Megumi, Chemical studies on the natural anthraquinones. I. Syntheses of munjistin, emodin, and 3-hydroxy-2-methylanthaquinone, Chem. Pharm. Bull., 1973, 21, 2790–2793.
15 J. Zhao, Z. Zhang, H. Chen and X. Chen, Studies on synthesis and anti-HIV RT activity of hypericin and ethylhypericin, Yaoxue Xuebao, 1998, 33, 67–71.
16 S. Aigner and H. Falk, A microwave-assisted synthesis of phananthroperylenes quinones as exemplified with hypericin, Monatsch. Chem., 2008, 139, 991–993.
17 Y. Mazur, H. Bock and D. Lavie, Preparation of Hypericin, US Pat. 5120412A, 1992.
18 L. Yip, J. B. Hudson, E. Gruszecka-Kowalik, L. H. Zalkow and T. G. H. Neil, Antiviral activity of a derivative of the photosensitive compound hypericin, Phytomedicine, 1996, 3, 185–190.
19 M. Waser, Y. Popova, C. W. Klampfl and H. Falk, 9,12-Dibenzothiazolylhypericin and 10,11-Dibenzothiazolyl-10,11-Diademethylhypericin: Photochemical Properties of Hypericin Derivatives Depending on the Substitution Site, Monatsch. Chem., 2005, 136, 1791–1797.
20 S. W. Kim, J. H. Park, S. D. Yang, M. G. Hur, Y.-S. Kim, J.-S. Chai, Y. S. Kim and K. H. Yu, Facile synthesis and
radiodiode labeling of hypericin, Bull. Korean Chem. Soc., 2004, 25, 1147–1150.

21 D. Geissmeier and H. Falk, ω,ω’-Appended nucleo-base derivatives of hypericin, Monatsh. Chem., 2008, 139, 1127–1136.

22 H. Falk and T. N. H. Tran, Synthesis and properties of an ω,ω’-appendened eighteen carbon chains hypericin derivative, Monatsh. Chem., 1996, 127, 717–723.

23 H. Falk and G. Schoppel, A synthesis of emodin anthrone, Monatsh. Chem., 1991, 122, 739–744.

24 H. J. Banks, D. W. Cameron and W. D. Raverty, Chemistry of Coccoidea. II. Condensed polycyclic pigments from two Australian pseudococcids (Hemiptera), Aust. J. Chem., 1976, 29, 1509–1521.

25 H. Falk and G. Schoppel, On the Synthesis of Hypericin by Oxidative Trimethylxymedin Anthrone and Emodin Anthrone Dimerization: Isohypericin, Monatsh. Chem., 1992, 123, 931–938.

26 D. Spitzner, Synthesis of photohypericin from emodin, Angew. Chem., 1977, 89, 55–56.

27 E. Gruszecka-Kowalik and L. H. Zalkow, An improved synthesis of hypericin and related compounds, Org. Prep. Proced. Int., 2000, 32, 57–61.

28 J. Motoyoshiya, Y. Masue, Y. Nishi and H. Aoyama, Synthesis of hypericin via emodin anthrone derived from a two-fold Diels-Alder reaction of 1,4-benzoquinone, Nat. Prod. Commun., 2007, 2, 67–70.

29 J. Berlanda, T. Kiesslich, V. Engelhardt, B. Krammer and K. Plaetzer, Comparative in vitro study on the characteristics of different photosensitizers employed in PDT, J. Photochem. Photobiol., B, 2010, 100, 173–180.

30 Y. D. Liu, X. L. Liu, Y. Xiao, F. M. Chen and F. N. Xiao, A multifunctional nanoplasform based on mesoporous silica nanoparticles for imaging-guided chemophotodynamic synergetic therapy, RSC Adv., 2017, 7, 31133–31141.

31 H. Fan, G. Yan, Z. Zhao, X. Hu, W. Zhang, H. Liu, X. Fu, T. Fu, X. Zhang and W. Tan, A smart photosensitizer-manganese dioxide nanosystem for enhanced photodynamic therapy by reducing glutathione levels in cancer cells, Angew. Chem., 2016, 55, 5477–5482.

32 L. B. Meng, W. Zhang, D. Li, Y. Li, X. Y. Hu, L. Wang and G. Li, pH-Responsive supramolecular vesicles assembled by water-soluble pillar[5]arene and a BODIPY photosensitizer for chemo-photodynamic dual therapy, Chem. Commun., 2015, 51, 14381–14384.

33 H. H. Fan, X. B. Zhang and Y. Lu, Recent advances in DNAzyme-based gene silencing, Sci. China: Chem., 2017, 60, 591–601.

34 H.-M. Meng, H. Liu, H. Kuai, R. Peng, L. Mo and X.-B. Zhang, Aptamer-integrated DNA nanostructures for biosensing, bioimaging and cancer therapy, Chem. Soc. Rev., 2016, 45, 2583–2602.

35 M. C. Montanha, L. L. Silva, F. B. B. Pangoni, G. B. Cesar, R. S. Goncalves, W. Caetano, N. Hioka, T. T. Tominaga, M. E. L. Consolaro, A. Diniz and E. Kimura, Response surface method optimization of a novel hypericin formulation in P123 micelles for colorectal cancer and antimicrobial photodynamic therapy, J. Photochem. Photobiol., B, 2017, 170, 247–255.

36 B. Kucharova, J. Mikes, R. Jendzelovsky, Z. Jendzelovska, J. Koval and P. Fedorocko, Potentiation of hypericin-mediated photodynamic therapy cytotoxicity by MK-886: focus on ABC transporters, GDF-15 and redox status, Photodiag. Photodyn. Ther., 2015, 12, 490–503.

37 J. Mikes, R. Jendzelovsky and P. Fedorocko, in Cellular aspects of photodynamic therapy with hypericin, Nova Science Publishers, Inc., 2013, pp. 111–147.

38 Y. Xu, D. Wang, Z. Zhuang, K. Jin, L. Zheng, Q. Yang and K. Guo, Hypericin-mediated photodynamic therapy induces apoptosis in K562 human leukemia cells through JNK pathway modulation, Mol. Med. Rep., 2015, 12, 6475–6482.

39 M. Maslanakova, L. Balogova, P. Miskovsky, R. Tkacova and K. Stroffekova, Anti- and Pro-Apoptotic Bcl2 Proteins Distribution and Metabolic Profile in Human Coronary Aorta Endothelial Cells Before and After HypPDT, Cell Biochem. Biophys., 2016, 74, 435–447.

40 A. M. Lima, C. D. Pizzol, F. B. F. Monteiro, T. B. Creczynski-Pasa, G. P. Andrade, A. O. Ribeiro and J. R. Perussi, Hypericin encapsulated in solid lipid nanoparticles: phototoxicity and photodynamic efficiency, J. Photochem. Photobiol., B, 2013, 125, 146–154.

41 D. Feinweber, T. Verwanger, O. Brueggemann, I. Teasdale and B. Krammer, Applicability of new degradable hypericin-polymer-conjugates as photosensitizers: principal mode of action demonstrated by in vitro models, Photochem. Photobiol. Sci., 2014, 13, 1607–1620.

42 A. Kubin, F. Wierrani, U. Burner, G. Alth and W. Gruenberger, Hypericin – the facts about a controversal agent, Curr. Pharm. Des., 2005, 11, 233–253.

43 P. Agostinis, A. Vantieghem, W. Merlevede and P. A. M. de Witte, Hypericin in cancer treatment: more light on the way, Int. J. Biochem. Cell Biol., 2002, 34, 221–241.

44 L. M. Davids, B. Kleemann, S. Cooper and S. H. Kidson, Melanomas display increased cytoprotection to hypericin-mediated cytotoxicity through the induction of autophagy, Cell Biol. Int., 2009, 33, 1065–1072.

45 G. Seitz, S. W. Warmann, S. Armeanu, H. Heitmann, P. Ruck, R. M. Hoffman, J. Fuchs and J. T. Wessels, In vitro photodynamic therapy of childhood rhabdomyosarcoma, Int. J. Oncol., 2007, 30, 615–620.

46 J. Zuschrader, W. Schoeberger and H. Falk, A carbohydrate-linked hypericin photosensitizing agent, Monatsh. Chem., 2008, 139, 1387–1390.

47 I. Teasdale, M. Waser, S. Wilfert, H. Falk and O. Brueggemann, Photoreactive, water-soluble conjugates of hypericin with polyphosphazenes, Monatsh. Chem., 2012, 143, 355–360.